Skip to main content

TScan Therapeutics, Inc. (TCRX)

NASDAQ: TCRX · IEX Real-Time Price · USD
7.58
-0.42 (-5.25%)
After-hours:Oct 25, 2021 4:11 PM EDT
8.00
0.21 (2.70%)
At close: Oct 25, 4:00 PM
Market Cap191.51M
Revenue (ttm)1.09M
Net Income (ttm)-26.13M
Shares Out23.94M
EPS (ttm)-1.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,408
Open7.82
Previous Close7.79
Day's Range7.62 - 8.19
52-Week Range6.06 - 14.71
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About TCRX

TScan Therapeutics is a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system ...

IndustryBiotechnology
IPO DateJul 16, 2021
CEODavid Southwell
Employees73
Stock ExchangeNASDAQ
Ticker SymbolTCRX
Full Company Profile

Financial Performance

Financial Statements

News

Wall Street Analysts See a 215% Upside in TScan Therapeutics, Inc. (TCRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 214.5% in TScan Therapeutics, Inc. (TCRX). While the effectiveness of this highly sought-after metric is question...

1 week ago - Zacks Investment Research

TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TC...

2 weeks ago - GlobeNewsWire

TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference

WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (T...

3 weeks ago - GlobeNewsWire

TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (T...

1 month ago - GlobeNewsWire

TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (T...

1 month ago - GlobeNewsWire

TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs

2 months ago - GlobeNewsWire

TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious ...

Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T ...

3 months ago - GlobeNewsWire

TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell...

3 months ago - GlobeNewswire

TScan Therapeutics IPO Registration Document (S-1)

TScan Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC